Immunogenicity and Safety Study of a Bivalent Human Papillomavirus (Type 16, 18) Recombinant Vaccine (E.Coli) in Healthy Female Subjects Aged 9 to 17 Years
Phase of Trial: Phase III
Latest Information Update: 12 Jan 2018
At a glance
- Drugs Human papillomavirus 16/18 vaccine recombinant bivalent Xiamen Innovax (Primary)
- Indications Human papillomavirus infections
- Focus Pharmacodynamics; Registrational
- 09 Jan 2018 Status changed from active, no longer recruiting to completed.
- 30 Dec 2015 Planned end date changed from 1 Jun 2016 to 1 Jul 2016, as reported by ClinicalTrials.gov.
- 30 Dec 2015 Planned primary completion date changed from 1 Jun 2016 to 1 Jul 2016, as reported by ClinicalTrials.gov.